Pancreatic cancer (PC) is an aggressive malignancy with a dismal prognosis. To improve
patient survival, the development of screening methods for early diagnosis is pivotal …

Background Pancreatic cancer is a deadly disease with a five-year survival of less than 5%.
A better understanding of the underlying biology may suggest novel therapeutic targets …

Pancreatic cancer (PC) is an aggressive disease with a high mortality and poor prognosis.
The human microbiome is a key factor in many malignancies, having the ability to alter host …

Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly
diagnosed when treatment with curative intent is not possible. Consequently, the overall five …

Pancreatic cancer (PC) is a common cause of cancer-related deaths. Current research
shows that prognostic biomarkers play a key role in the treatment of PC. This study aimed to …

Pancreatic cancer is a formidable disease and represents a major public health problem.
Globally, around 496,000 cases of pancreatic cancer are diagnosed each year, with almost …

Pancreatic cancer (PC) is a leading cause of cancer-related death in developed countries,
and since most patients have incurable disease at the time of diagnosis, developing a …

Pancreatic cancer is a highly aggressive cancer with an exceedingly low rate of response to
treatments, which calls for comprehensive molecular characterization of pancreatic cancer …

Pancreatic cancer is the fourth leading cause of cancer-related death in the world. The
etiology of pancreatic cancer is heterogeneous with a wide range of alterations that have …

The epigenomic abnormality of pancreatic ductal adenocarcinoma (PDAC) has rarely been
investigated due to its strong heterogeneity. Here, we used single-cell multiomics …